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Long-term Clinical Outcomes Following Elective
Stent Implantation for Unprotected Left Main
Coronary Artery Disease
Wei-Syun Hu, Shih-Huang Lee, Chiung-Zuan Chiu, Kou-Gi Shyu, Shen-Chang Lin, 
Huei-Fong Hung, Jer-Young Liou, Jun-Jack Cheng*
Background/Purpose: Percutaneous coronary intervention (PCI) has been increasingly adopted for 
unprotected left main coronary artery (LMCA) disease. The aim of this study was to evaluate the predictors
of long-term clinical outcomes in patients after elective stent implantation for unprotected LMCA disease.
Methods: A total of 122 patients with medically refractory angina who received coronary stenting for 
unprotected LMCA disease between August 1997 and December 2008 were included.
Results: During the follow-up period of 45±35 months (range: 1–137 months), the incidence of repeated PCI
and/or coronary artery bypass grafting (CABG), and cardiovascular and total mortality were 28% (34 patients),
20% (24 patients), and 25% (31 patients), respectively. Multivariate analysis revealed that young age
[p = 0.02; hazard ratio (HR): 2.19, 95% confidence interval (CI): 1.11–4.30] and bare-metal stent (BMS)
use (p = 0.02; HR: 5.35, 95% CI: 1.27–22.57) were the independent predictors of repeated PCI and/or
CABG. Only lower left ventricular ejection fraction (LVEF) could predict both cardiovascular mortality
(p=0.003; HR: 4.25, 95% CI: 1.63–11.08) and total mortality (p=0.002; HR: 3.95, 95% CI: 1.65–9.45). Lower
LVEF (p= 0.001; HR: 0.31, 95% CI: 0.16–0.61) and small stent size (p= 0.01; HR: 5.95, 95% CI: 1.43–24.80)
could predict the composite endpoint, including target vessel revascularization and total mortality.
Conclusion: We showed that young age and BMS implantation could predict repeated PCI and/or CABG
after stent implantation for unprotected LMCA disease. Only lower LVEF could predict both cardiovascular
and total mortality. Lower LVEF and small stent size but not BMS implantation could predict composite
target vessel revascularization/total mortality.
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Unprotected left main coronary artery (LMCA)
disease is considered to be a class II A or II B in-
dication for percutaneous coronary intervention
(PCI), according to current guidelines if coronary
artery bypass grafting (CABG) is not a viable 
option.1,2 Several studies have revealed that PCI
for unprotected LMCA disease can be considered
in selected patients.3–8 Recently, drug-eluting stent
(DES) placement has been recommended if PCI
is undertaken in unprotected LMCA disease.9–13
However, the predictors of long-term clinical
outcomes in this patient population have not
been well established.9–14 Therefore, the purpose
of our study was to investigate the predictors of
long-term clinical outcomes in patients after elec-
tive stent implantation for unprotected LMCA
disease.
Methods
Study population
From August 1997 to December 2008, 136 pa-
tients with medically refractory angina received
elective coronary stenting at our institute for un-
protected LMCA disease with angiographic evi-
dence of > 50% diameter stenosis. Follow-up was
absent in 14 patients, thus a total of 122 patients
were included. The decision for stent implan-
tation instead of surgical revascularization was
considered when one of these two conditions was
present; those who presented as highly symptom-
atic but inoperable because of comorbidity or
those who refused CABG with a preference for
PCI. Informed consent forms on the treatment
choice between LMCA stenting or CABG was 
obtained from all patients before the procedure.3,6
Stent implantation
All patients were treated with the percutaneous
trans-femoral approach via an angiography sheath
and the standard angioplasty technique.3,6 Each
patient received intravenous heparin (100 U/kg),
and, if necessary, an additional bolus of heparin
was administered to maintain activated clotting
time at > 5 minutes. Quantitative angiographic
analysis was performed to demonstrate the steno-
sis in its most severe and non-foreshortened pro-
jection. With the use of a contrast-filled guiding
catheter as the calibration standard, reference and
lesion minimal lumen diameter were determined.
Successful immediate outcome of stent implan-
tation for LMCA disease was defined as < 30%
residual stenosis. Myocardial infarction (MI) was
diagnosed by a rise in the creatine kinase level to
more than twice the upper normal limit, with an
increased creatine kinase MB fraction. Post-stenting
medications included aspirin (100 mg/day) and
clopidogrel (75 mg/day). Therapy was continued
for 3 months in patients who received a bare-metal
stent (BMS) and 12 months in those who re-
ceived a DES, and aspirin was continued indefi-
nitely. The choice between BMS and DES was left
to the patients’ preference because our insurance
system does not cover the fee for DES. Clinical
follow-up was obtained by clinical visits, telephone
conversation, and chart review.3,6
Predictors of long-term cardiovascular
outcomes
The outcomes analyzed for follow-up were tar-
get vessel revascularization (TVR), cardiovascular
death, all-cause mortality, and composite TVR/
total mortality. TVR was defined as any repeated
revascularization (either PCI or CABG) to treat a
luminal re-narrowing within the stent, or within
5-mm borders adjacent to the stent. Any death
was considered cardiac unless proven otherwise.
The analyzed variables included: age (≥ 65 years
or < 65 years); sex; a history of prior MI or PCI;
smoking; diabetes mellitus; hypertension; anemia
(hemoglobin < 13 mg/dL in men, < 11 mg/dL in
women); chronic renal insufficiency (serum cre-
atinine ≥ 2 mg/dL); hypercholesterolemia (low-
density lipoprotein ≥ 130 mg/dL); left ventricular
ejection fraction (LVEF) (≥ 40% or < 40%); posi-
tion of LMCA stenosis (proximal, middle or dis-
tal); stent size (≥ 4.0 mm or < 4.0 mm); and stent
type (BMS or DES).
Statistical analysis
Continuous variables were shown as mean ±
standard deviation, and categorical variables were
presented as counts and percentages. Event-free
survival at follow-up was evaluated according to
the Kaplan-Meier method, and survival among
groups was compared with the log-rank test.
Multivariate analysis was performed with a Cox
regression model to determine the independent
predictors of the long-term outcomes. Variables
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selected to be tested in the multivariate analysis
were those with a p value < 0.1 in the univariate
model. A p value < 0.05 was considered statis-
tically significant, and confidence interval (CI)
was 95%.
Results
Immediate and long-term outcomes of 
stent implantation
Basic clinical and angiographic characteristics of
the 122 patients are shown in Table 1. The LMCA
lesions were treated with BMSs (75%) or DESs
(25%). The mean stent size was 3.3 ± 0.4 mm,
and the mean length was 16 ± 6 mm. A total of
15% (18 patients), 16% (20 patients), and 69%
(84 patients) had proximal, middle, and distal
left main lesions, respectively. Among the 84 pa-
tients with distal left main lesion, 66 received
simple crossover stenting. Out of the 66 patients
who received simple crossover stenting, kissing
balloon post-dilatation was performed in 44 pa-
tients. The remaining 18 patients received bifur-
cation stenting, of whom, four received T stenting,
10 Cullotte stenting, and four Crush stenting.
Kissing balloon post-dilatation was performed in
all 18 patients who received bifurcation stenting.
Patients with pure LMCA lesions, LMCA plus
one-vessel disease, LMCA plus two-vessel dis-
ease, and LMCA plus three-vessel disease were
20% (24 patients), 24% (29 patients), 39% (48
patients), and 17% (21 patients), respectively.
Ninety-eight patients (80%) received PCI in other
coronary arteries at the time of LMCA stenting,
in which right coronary artery stenting was per-
formed in 47 patients, whereas PCI of three ves-
sels in addition to LMCA stenting was achieved
in 21 patients. Immediate success was achieved in
all of the patients without major complications.
During a follow-up period of 45 ± 35 months
(range: 1–137 months), 34 patients (28%) un-
derwent repeated coronary intervention for re-
current angina; 19 (16%) received PCI, 12 (10%)
CABG, and three (2%) both PCI and CABG for
restenosis of LMCA. In the three patients who re-
ceived both PCI and CABG, the LMCA stenosis
was located in the distal portion, and simple
crossover stenting was performed at the first time
of LMCA stenting. All three patients received re-
peated PCI within 6 months because of LMCA
restenosis and/or ostial side branch restenosis.
Unfortunately, all three patients needed to receive
CABG soon because of LMCA restenosis and/or
new stenosis of other coronary arteries.
Thirty-one patients (25%) died: 24 (20%) with
cardiovascular disease and seven (5%) with non-
cardiovascular disease. In the six deaths within 
3 months after LMCA stenting, five were due to
acute MI, and one of these had received a second
PCI. The other patient died from congestive heart
failure after CABG for unstable angina (Table 2).
Table 1. Basic clinical and angiographic
characteristics of total 122 patients
Age (yr) 70 ± 10
Sex, female 38 (31)
Prior MI 27 (22)
Prior PCI 60 (49)
Smoking 51 (42)
Diabetes mellitus 49 (40)
Hypertension 91 (75)
Anemia 42 (34)
Chronic renal insufficiency 14 (12)
Hypercholesterolemia 67 (55)
LVEF ≤ 40% 16 (13)
Position of LMCA stenosis
Proximal 18 (15)
Middle 20 (16)
Distal 84 (69)
Mean stent size (mm) 3.3 ± 0.4
Mean stent length (mm) 16 ± 6
Bare-metal stent 92 (75)
Pure LMCA disease 24 (20)
LMCA plus 1-vessel disease 29 (24)
LMCA plus 2-vessel disease 48 (39)
LMCA plus 3-vessel disease 21 (17)
*Data presented as n (%) or mean ± standard deviation. LMCA =
left main coronary artery; LVEF = left ventricular ejection frac-
tion; MI = myocardial infarction; PCI = percutaneous coronary 
intervention.
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The Figure shows the Kaplan-Meier curve for free-
dom from TVR, cardiovascular death, total death,
and composite TVR/total mortality at follow-up.
Predictors of repeated PCI and/or CABG
Univariate analysis revealed that young age (p =
0.003), lower LVEF (p = 0.08), small stent size
(p = 0.01), and BMS use (p = 0.01) were related to
repeated PCI and/or CABG (Table 3). Multivariate
analysis showed that young age [p = 0.02; hazard
ratio (HR): 2.19, 95% CI: 1.11–4.30] and BMS use
(p = 0.02; HR: 5.35, 95% CI: 1.27–22.57) were
independent predictors of TVR.
Predictors of cardiovascular mortality
Univariate analysis revealed that anemia (p <
0.001), chronic renal insufficiency (p< 0.001), and
lower LVEF (p < 0.001) were related to cardiovas-
cular mortality (Table 3). Multivariate analysis
showed that only lower LVEF could predict the
presence of cardiovascular mortality (p = 0.003;
HR: 4.25, 95% CI: 1.63–11.08).
Predictors of total mortality
Univariate analysis revealed that anemia (p <
0.001), chronic renal insufficiency (p < 0.001),
lower LVEF (p < 0.001), and position of LMCA
Table 2. Clinical data of patients with mortality
Patient no. Repeated PCI CABG Mortality reasons Follow-up (d)
1 N Y Sepsis 606
2 Y N Acute myocardial infarction 387
3 N N Congestive heart failure 2400
4 N Y Acute myocardial infarction 3853
5 N Y Esophageal varices bleeding 3610
6 N N Acute myocardial infarction 27
7 Y Y Congestive heart failure 89
8 Y N Congestive heart failure 3087
9 N N Congestive heart failure 3424
10 N N Pneumonia 2210
11 N N Acute myocardial infarction 2876
12 Y N Acute myocardial infarction 2327
13 N N Traffic accident 1542
14 Y Y Acute myocardial infarction 2630
15 N N Acute myocardial infarction 204
16 Y N Congestive heart failure 628
17 N N Congestive heart failure 358
18 Y N Acute myocardial infarction 1889
19 Y N Acute myocardial infarction 58
20 N N Colon carcinoma 553
21 N N Congestive heart failure 111
22 Y N Acute myocardial infarction 796
23 N N Congestive heart failure 1469
24 N N Congestive heart failure 704
25 N N Congestive heart failure 1053
26 N N Acute myocardial infarction 68
27 N N Acute myocardial infarction 156
28 N N Pneumonia 370
29 N Y Sepsis 161
30 N N Acute myocardial infarction 24
31 N N Acute myocardial infarction 77
CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention; Y = yes; N = no.
stenosis (p = 0.07) were associated with total
mortality (Table 3). Multivariate analysis showed
that only lower LVEF could predict the presence
of total mortality (p = 0.002; HR: 3.95, 95% CI:
1.65–9.45).
Predictors of composite TVR/total mortality
Univariate analysis revealed that anemia (p =
0.02), chronic renal insufficiency (p=0.099), lower
LVEF (p < 0.001), and small stent size (p = 0.01)
were associated with composite TVR/total mortal-
ity (Table 3). Multivariate analysis showed that
lower LVEF (p = 0.001; HR: 0.31, 95% CI: 0.16–
0.61) and small stent size (p= 0.01; HR: 5.95, 95%
CI: 1.43–24.80) could predict composite TVR/total
mortality.
Discussion
Major findings
The present study showed that young age and
BMS use could predict repeated PCI and/or CABG
in patients after stent implantation for unprotected
LMCA disease. Only lower LEVF could predict
both cardiovascular and total mortality.
Comparisons with previous studies
Previous studies have shown that in-hospital mor-
tality is around 0–3% after stent implantation 
in patients with unprotected LMCA disease.6–10
In the present study, none of the patients had in-
hospital mortality after stenting of unprotected
LMCA stenosis. However, six of 24 cardiovascular
deaths occurred within the first 3 months after
stent implantation. This finding suggests that stent
thrombosis plays an important role in early car-
diovascular mortality. The present study suggests
that PCI should only be considered in selected
patients.
Predictors of repeated PCI and/or CABG
Price et al have reported that impaired renal func-
tion can predict TVR in patients who receive DES
implantation for unprotected LMCA disease.10
Previous studies have shown that the incidence
of TVR after unprotected LMCA stenting was
17–31% in the BMS era and 2–14% in the DES
era.9–11,15–19 The present study also showed that
patients in the DES group had significantly lower
rates of TVR than those in the BMS group. Cameron
et al have demonstrated that young age and fe-
male sex can predict recurrent angina within 1 year
of CABG for coronary artery disease.20 Our previ-
ous study has shown that young age and female
sex can predict repeated revascularization after
unprotected LMCA stenting.6 The present study
found that BMS use and young age could predict
repeated PCI and/or CABG after stent implanta-
tion for unprotected LMCA disease. Furthermore,
some previous studies have found that maximal
balloon inflation pressure correlates with occur-
rence of angiographic restenosis in patients after
unprotected LMCA stenting.9,10 These findings
suggest that small vessel size explains the higher
incidence of restenosis after stent implantation
for unprotected LMCA disease. The present study
revealed that the patients who needed repeated
PCI and/or CABG tended to have small stent
size; however, the stent size was not a predictor
of repeated PCI and/or CABG.
Predictors of cardiovascular mortality
Our previous study has shown that lower LVEF 
is associated with cardiovascular mortality after
unprotected LMCA stenting.6 Meliga et al have
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Figure. Kaplan-Meier curve showing freedom from target
vessel revascularization, cardiovascular death, total death, and
composite target vessel revascularization/total mortality at
follow-up.
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reported that lower LVEF, old age, shock, and
EuroSCORE (European System for Cardiac
Operative Risk Evaluation) were associated with
cardiovascular mortality.13 Tamburino et al have
shown that lower LVEF, diabetes mellitus, and
reference vessel diameter are predictive of cardio-
vascular mortality after stent implantation for
unprotected LMCA disease.8 The present study
showed that only lower LVEF could predict car-
diovascular mortality after coronary stenting for
unprotected LMCA disease.
Predictors of total mortality
Price et al have reported that impaired renal
function is the only predictor of total mortality.10
Palmerini et al have shown that lower LVEF, acute
coronary syndrome and peripheral vascular dis-
ease can predict total mortality after stent implan-
tation for unprotected LMCA disease.12 Tamburino
et al have demonstrated that lower LVEF, diabetes
mellitus, and EuroSCORE were predictors of
total mortality.8 The present study and our previ-
ous study have shown that lower LVEF but not
impaired renal function could predict total mor-
tality after stent implantation for unprotected
LMCA disease.6
Predictors of composite TVR/total mortality
Valgimigli et al have revealed that reference vessel
diameter is predictive of major adverse cardio-
vascular events (MACEs) after stent implantation
for unprotected LMCA disease.15 Price et al have
reported that chronic renal insufficiency is an in-
dependent predictor of MACEs.10 Furthermore,
some studies have found that DES implantation
could predict lower MACE rate in patients who
are receiving unprotected LMCA stenting.8,9,15
The present study showed that lower LVEF and
small stent size, but not BMS implantation, could
predict composite TVR/total mortality.
Limitations
First, the number of patients was small. Second,
angiographic follow-up was only performed in pa-
tients with clinical presentation or non-invasive
evaluation, which suggested the presence of 
myocardial ischemia, which led to possible under-
estimation of the restenosis rate of LMCA stenting.
Third, patients were treated in a time frame in
which evolution of devices (such as intravascular
ultrasonography and DES) and operator experi-
ence might have had an impact on outcomes.
Finally, because we did not routinely perform
echocardiography or right heart catheterization in
each patient, we could not provide EuroSCORE
and Parsonnet score for the study populations.
Also, SYNTAX score could not be provided be-
cause of the extended time period in this study
when SYNTAX score was not available. Despite
these limitations, long-term clinical outcomes fol-
lowing stent implantation for unprotected LMCA
disease are still relatively acceptable.
In conclusion, the present study showed that
young age and BMS implantation could predict
repeated PCI and/or CABG in patients after stent
implantation for unprotected LMCA disease. Only
lower LVEF could predict both cardiovascular and
total mortality. Lower LVEF and small stent size,
but not BMS implantation, could predict compos-
ite TVR/total mortality.
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